Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 3 3Phase 1/2 2

Status

Recruiting 3

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2Neoadjuvant Therapy 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 183Docetaxel 167Gemcitabine 165Oxaliplatin 162Carboplatin 161Paclitaxel 152Leucovorin 122Drug Therapy 119Dexamethasone 119Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 57Neoadjuvant Therapy 53Lenalidomide 52Letrozole 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × OTHER × famitinib × Clear all
NCT06913777 2025-06-06

Neoadjuvant SNF Precision Therapy Phase III

Fudan University

Phase 3 Recruiting
404 enrolled

Neoadjuvant Therapy

NCT05999149 2024-02-21

BCTOP-T-N01

Fudan University

Phase 3 Recruiting
424 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05760378 2024-02-06

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Fudan University

Phase 3 Recruiting
223 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡